Home News and Analysis Deals & Exits

Deals & Exits

It's not just business as usual for investors; many are seeing an uptick in activity as this has the feel of the busiest fall season in memory.
wealth tech
The sector has been slow to digitize but with consumer attitudes toward the market changing quickly innovation is imminent.
Venture lending is seen as offering higher returns for higher risk. So why, against such a volatile backdrop, is fundraising surging ahead?
The Silicon Valley veteran talks about his investment in Rigetti and why he says there is a lot of excitement regarding the nascent field of quantum computing.
LatAm
After a record year in 2019, investors remain bullish on the region and say the momentum will continue far past 2020's uncertainties.
Tom Walker of Rev1 Ventures addresses the question of whether investors should back biotech start-ups that focus on the coronavirus and other potential pandemics. Here's what you should know.
Biotech
Appetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.
The online provider of personal healthcare will likely not be doing a reverse merger with a SPAC soon, according to a venture source.
As more venture firms become accustomed to virtual pitches, they’re emphasizing reference checks and setting up multiple Zoom calls as a way to verify their investments and better get to know the founders.
VC is not entirely insulated from the impact of the pandemic and economic slowdown, but it sure feels like it really is business as usual.
vcj
vcj

Copyright PEI Media

Not for publication, email or dissemination